$0.55
▼ -2.2% Today
as of Jul 22, 16:47 ET
Last 30 days
Recent Press Releases & News
Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption
Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies
Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting
Overview
52-week range
$0.48
$2.48
4% of range
Avg surprise (last 1)
-17.6%
Avg reaction (last 2)
+8.2%
50% positive
Latest IV / EM
189%
EM ±43.9% · $1 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Fri May 15, 2026 | Mar/2026 | $-0.95 | — | — | +25.2% | -2.8% | earnings |
| Wed Dec 31, 2025 | Dec 2025 | $-0.38 | — | — | — | — | financials |
| Tue Aug 12, 2025 | Jun/2025 | $-0.80 | — | — | — | — | earnings |
| Wed May 14, 2025 | Mar/2025 | $-1.27 | $-1.08 | -17.6% | — | +19.2% | earnings |
| Tue Dec 31, 2024 | Dec 2024 | $-1.30 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-1.57 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-1.34 | — | — | — | — | financials |
| Sun Dec 31, 2023 | Dec 2023 | $-1.45 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.06 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Tue Aug 11, 2026 | Jun/2026 | OTHER | -$0.36 | -$0.80 | +55.0% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2M | $4M | — | — | — | — | — | — |
| Cost of revenue | $328,878 | $789,208 | — | — | — | — | — | — |
| Gross profit | $1M | $3M | — | — | — | — | — | — |
| Operating income | $-32M | $-9M | — | $-9M | $-11M | $-10M | — | $-11M |
| Net income | — | — | — | — | $-12M | $-10M | — | $-11M |
| EPS (diluted) | $-0.95 | $-0.38 | — | $-0.80 | $-1.27 | $-1.30 | — | $-1.57 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $5M | $8M | $4M | $6M | $26,410 | $1M | $3M | $18M |
| Inventory | $23M | $23M | $22M | $17M | $15M | $14M | $8M | — |
| Total current assets | $32M | $38M | $28M | $25M | $18M | $18M | $14M | $28M |
| Total assets | $133M | $140M | $131M | $128M | $121M | $121M | $117M | $97M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $63M | $47M | $53M | $60M | $58M | $52M | $43M | $11M |
| Total equity | $62M | $80M | $68M | $65M | $61M | $65M | $70M | $86M |